A significant number of women under 50 are not receiving breast cancer screenings, missing out on vital early detection. Current guidelines primarily focus on genetic factors, overlooking lifestyle and other critical aspects for younger women. However, a new risk assessment tool called Boadicea, developed by Cambridge and funded by Cancer Research UK, has shown a more comprehensive approach by considering family history, lifestyle, reproductive history, and genetic information.
The existing criteria set by the National Institute of Health and Care Excellence (NICE) are failing to identify the majority of women under 50 who are at risk of developing breast cancer within the next decade. This has led to calls for a reassessment of the screening criteria to ensure early detection and intervention for this age group.
Breast cancer is a prevalent form of cancer globally, representing a significant portion of cancer cases and a leading cause of mortality among women under 50. Despite this, the guidelines provided to General Practitioners in England are missing up to 95% of women under 50 who could develop the disease within ten years. Experts emphasize the importance of identifying high-risk individuals early to enhance treatment outcomes and possibly prevent breast cancer.
Dr. Juliet Usher-Smith from the University of Cambridge emphasizes the need for improved identification of women at high risk to facilitate early intervention. The current NICE criteria are shown to overlook a large percentage of younger women who may develop breast cancer, indicating a necessity for reevaluation based on recent findings.
While acknowledging the practical challenges, Prof Montserrat García-Closas from the ICR highlights the need to strike a balance between the ease of implementation and the effectiveness of risk assessment. Dr. Simon Vincent, the chief scientific officer at Breast Cancer Now, supports the study’s findings, underscoring the imperative for a review of the current guidelines to ensure effective risk assessment and adequate investment in family history services within the NHS.
NICE has acknowledged the potential benefits of multifactorial risk models in enhancing the identification of women at increased risk of breast cancer. However, they maintain that the existing familial breast cancer guideline will not be modified without further evidence to support such changes. NICE remains committed to assessing new data and updating guidelines as warranted by clinical outcomes and feasibility studies.